List of Excipients in Branded Drug IRENKA

Generic Drugs Containing IRENKA

Company	Ingredient	NDC	Excipient
LUPIN PHARMA	duloxetine	27437-298	AMMONIA
LUPIN PHARMA	duloxetine	27437-298	CROSCARMELLOSE SODIUM
LUPIN PHARMA	duloxetine	27437-298	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in IRENKA?

# Of NDCs	Excipient
1	AMMONIA
1	CROSCARMELLOSE SODIUM
1	FERROSOFERRIC OXIDE

Irenka Excipient Strategy and Commercial Opportunities in Duloxetine Delayed-Release Capsules

Last updated: August 22, 2026

Irenka is a duloxetine hydrochloride delayed-release capsule used for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Its commercial value is tied less to the active ingredient, which is broadly genericized, than to delayed-release performance, capsule stability, manufacturing efficiency, dosage-form differentiation, and access to institutional and specialty channels.

The strongest excipient opportunities involve enteric protection, coating-process optimization, capsule-shell substitution, sprinkle-compatible delivery, and differentiated dosage strengths. Duloxetine products require protection from gastric exposure and must meet dissolution specifications across acidic and intestinal media. Those technical requirements create formulation and manufacturing barriers even after core compound and Orange Book exclusivity have expired.

What is Irenka and what dosage form does it use?

Irenka contains duloxetine hydrochloride in delayed-release capsules. The product uses enteric-coated drug-containing units, typically pellets or particles, rather than an immediate-release powder-filled capsule.

Attribute	Irenka
Active ingredient	Duloxetine hydrochloride
Dosage form	Delayed-release capsule
Therapeutic class	Serotonin-norepinephrine reuptake inhibitor
Typical strengths	20 mg, 30 mg, 40 mg and 60 mg
FDA pathway	Prescription drug application for duloxetine delayed-release capsules
Primary release site	Intestinal tract
Key formulation requirement	Protection from gastric release
Principal commercial comparators	Cymbalta and generic duloxetine delayed-release capsules
Main formulation barrier	Reproducible enteric dissolution and stability

Duloxetine is acid-sensitive. An enteric coating limits release in the stomach and allows dissolution after transit into higher-pH intestinal fluid. The dosage form must also control moisture exposure because hydrolytic and oxidative degradation can affect assay, impurities, dissolution and shelf life.

What excipients are used in Irenka-style duloxetine capsules?

Public duloxetine delayed-release labels identify excipient categories that generally include enteric polymers, coating aids, anti-tacking agents, plasticizers, pellet substrates and capsule-shell materials. Exact excipient composition can differ among approved manufacturers and strengths.

Formulation function	Common excipient category	Commercial purpose
Drug-layer substrate	Sugar spheres or microcrystalline cellulose-based pellets	Provides a uniform surface for drug layering
Binder	Hydroxypropyl cellulose or hypromellose	Improves adhesion of duloxetine to starter pellets
Enteric polymer	Hypromellose acetate succinate or methacrylic acid copolymer	Delays release until intestinal pH
Plasticizer	Triethyl citrate or equivalent	Reduces coating brittleness
Anti-tacking agent	Talc or colloidal silicon dioxide	Prevents pellet agglomeration during coating
Opacifier	Titanium dioxide	Controls capsule or coating appearance
Capsule shell	Gelatin or hypromellose	Encapsulates coated pellets
Colorants	Approved iron oxides or FD&C/D&C colorants	Supports strength identification and product branding
Surfactant	Sodium lauryl sulfate or equivalent	Supports wetting and coating uniformity

The most strategically important excipients are the enteric polymer, plasticizer and anti-tacking system. These materials determine coating integrity, acid resistance, intestinal release, mechanical durability and scale-up performance.

Which excipients have the greatest technical value?

Enteric polymer selection has the highest impact on product performance. Hypromellose acetate succinate, methacrylic acid copolymers and polyvinyl acetate phthalate can provide different dissolution profiles, processing temperatures and moisture barriers.

The polymer must satisfy four requirements:

1. Minimal release during the acid stage.
2. Prompt release after intestinal pH transition.
3. Adequate film strength during capsule filling and shipping.
4. Stability over the proposed shelf life.

Plasticizer concentration is also critical. Too little plasticizer can produce a brittle film that cracks during processing. Too much can lower the glass-transition temperature, increase tackiness and alter dissolution.

Talc, colloidal silicon dioxide and related anti-tacking agents influence coating yield and pellet separation. Their commercial importance is often underestimated because they affect manufacturing throughput rather than pharmacological performance. In a high-volume generic product, lower coating defects and shorter drying cycles can have a material effect on cost of goods.

What patents protect Irenka and duloxetine delayed-release formulations?

The principal duloxetine compound patents have expired in the United States. Commercial protection now depends primarily on regulatory status, formulation know-how, manufacturing controls, supplier qualification and any remaining jurisdiction-specific rights.

Patent or protection category	Relevance to Irenka	Current commercial significance
Duloxetine compound patents	Protected the active pharmaceutical ingredient	Expired in major markets
Delayed-release formulation patents	Covered enteric-coated duloxetine dosage forms or release control	Historically important; many rights have expired
Method-of-use patents	Covered approved indications such as depression or neuropathic pain	Generally weak against approved generic substitution where use claims are carved out
Process patents	May cover pellet layering, coating or drying parameters	Potentially relevant if unexpired and claim scope is enforceable
Excipient-combination claims	May cover specific polymer, plasticizer or coating systems	Product-specific freedom-to-operate issue
Manufacturing know-how	Controls coating thickness, drying, moisture and dissolution	Often more commercially important than expired composition patents

The major branded duloxetine product was Cymbalta, marketed by Eli Lilly. Its principal U.S. compound patent protection expired in the early 2010s, followed by generic entry. Irenka entered the market during the period when duloxetine delayed-release products were transitioning from branded to generic competition.

A current freedom-to-operate analysis requires a live patent-family review in each target jurisdiction. The critical search fields are:

• Duloxetine hydrochloride delayed-release capsules.
• Enteric-coated pellets containing duloxetine.
• Hypromellose acetate succinate and duloxetine combinations.
• Methacrylic acid copolymer coatings.
• Sprinkle capsules and openable delayed-release capsules.
• Low-moisture formulations.
• Continuous fluid-bed coating processes.
• Capsule-shell and colorant combinations.

When did duloxetine lose exclusivity?

Duloxetine lost meaningful U.S. compound exclusivity in the early 2010s. Generic duloxetine delayed-release capsules subsequently entered the U.S. market, creating substantial price competition.

Milestone	Timing
Cymbalta U.S. approval	2004
Initial branded market period	2004 to early 2010s
Core U.S. patent expiry period	Early 2010s
Generic duloxetine entry	2013 onward
Current market structure	Predominantly generic, with limited branded differentiation

The commercial effect of patent expiry was significant because duloxetine is used chronically and has several high-volume indications. Once multiple generic suppliers qualified, price became the dominant competitive variable for conventional 20 mg, 30 mg, 40 mg and 60 mg capsules.

What is the FDA regulatory status of Irenka?

Irenka is an FDA-regulated prescription duloxetine delayed-release capsule. The relevant regulatory standard is therapeutic equivalence to the reference product, generally demonstrated through abbreviated or 505(b)(2)-type regulatory pathways depending on the applicant and product history.

FDA review focuses on:

• Assay and impurity controls.
• Content uniformity among pellets and capsules.
• Acid-stage dissolution.
• Buffer-stage dissolution.
• Stability under long-term and accelerated conditions.
• Bioequivalence.
• Capsule-shell performance.
• Manufacturing-process validation.

For a generic duloxetine product, the principal regulatory risk is dissolution performance. A product can meet assay and content-uniformity requirements while failing acid resistance, delayed release or post-acid dissolution criteria.

The Orange Book status of an individual Irenka listing must be confirmed against the current FDA Orange Book because product listings, marketing status and patent certifications can change. A historical brand name should not be treated as evidence that the product remains actively marketed.

What formulation patents protect duloxetine delayed-release capsules?

Formulation patents may protect the dosage form even when the active ingredient is off patent. The highest-value claim areas are:

Enteric-coated pellet architecture

Claims may define a drug-layered core surrounded by a seal coat and enteric layer. The claim scope can depend on:

• Polymer identity.
• Polymer weight percentage.
• Coating thickness.
• Pellet particle-size distribution.
• Acid-stage release threshold.
• Intestinal-stage release window.
• Presence of a seal coat.

Moisture-protection systems

Duloxetine formulations can benefit from low-water-activity excipients, protective overcoats, desiccant packaging and moisture-resistant blister systems. These approaches may support a longer shelf life or reduce impurity growth.

Sprinkle and openable capsules

A capsule that can be opened and sprinkled over soft food can target patients with swallowing difficulty. The commercial value depends on maintaining pellet integrity and enteric performance after administration with food.

Alternative capsule shells

Hypromellose capsules can support vegetarian positioning and may provide different moisture behavior from gelatin. Shell substitution requires compatibility studies because shell moisture can affect pellet stability and dissolution.

Manufacturing-process claims

Fluid-bed coating conditions, atomization settings, inlet temperature, spray rate and drying endpoints can produce a practical barrier even where broad formulation claims are unavailable. Process claims are strongest when they correlate with a defined dissolution or impurity profile.

How strong is the patent estate for Irenka?

The overall patent estate is weak for exclusivity based solely on the active ingredient. Duloxetine is a mature generic molecule, and conventional delayed-release capsule technology is established.

The estate can be stronger for a differentiated formulation if the product includes:

• A new release profile.
• A clinically meaningful administration advantage.
• A proprietary sprinkle or pediatric presentation.
• A validated low-moisture system.
• A difficult-to-copy pellet architecture.
• A combination of excipients that produces an unexpected stability or dissolution result.

Protection layer	Relative strength
Duloxetine molecule	Low after expiry
Conventional delayed-release capsule	Low to moderate
Specific pellet architecture	Moderate
Sprinkle dosage form	Moderate if clinically differentiated
Novel excipient combination	Moderate, subject to claim scope
Manufacturing process	Moderate if process-specific and difficult to design around
Packaging and stability system	Low as a standalone barrier, higher as know-how
Method of use	Low against generic competition where indication carve-outs are available

An excipient strategy should not rely on a single polymer patent. The preferred structure is a layered protection program combining formulation claims, process claims, analytical specifications, supplier agreements, trade secrets and regulatory differentiation.

What commercial opportunities exist for Irenka excipients?

Lower-cost generic supply

The largest opportunity is cost reduction in established duloxetine products. Excipient suppliers can compete through:

• Higher-solids coating systems.
• Lower spray-drying energy requirements.
• Reduced coating weight.
• Improved anti-tacking performance.
• Fewer coating defects.
• Shorter process cycle times.
• Consistent global supply.

A supplier that reduces coating time or batch failure rates can win business even when the excipient itself carries a low unit price.

Premium capsule-shell positioning

Hypromellose capsules create a potential differentiation route for vegetarian, religious-compliance and moisture-control requirements. The opportunity is limited in a pure commodity market but can support private-label, hospital and international tenders.

Sprinkle-friendly products

A capsule that can be opened without damaging enteric-coated pellets can address dysphagia and selected institutional-care settings. The formulation must demonstrate that pellets remain intact when mixed with approved soft foods and are not chewed.

Pediatric and geriatric presentations

Duloxetine has established use in adults, but age-specific product opportunities may exist where the regulatory pathway supports a new presentation. Liquid formulations are technically difficult because duloxetine requires protection from gastric conditions. Multiparticulate granules or sachets may be more practical than a conventional liquid.

Regional licensing

Companies with validated duloxetine pellet technology can license:

• Formulation packages.
• Coating-process parameters.
• Stability data.
• Regulatory files.
• Capsule-shell systems.
• Manufacturing transfer support.

Potential licensees include generic manufacturers in markets where duloxetine remains under-supplied or where local production is favored.

Hospital and institutional channels

Institutional buyers may value consistent availability, dose flexibility and administration options more than retail branding. A 20 mg capsule and sprinkle-compatible product can improve formulary utility, but the economic case depends on tender pricing and evidence that the product reduces administration burden.

Which companies are challenging or competing with Irenka?

Irenka competes primarily with:

• Eli Lilly's Cymbalta.
• Generic duloxetine manufacturers.
• Authorized generic suppliers.
• Regional manufacturers of duloxetine delayed-release capsules.
• Potential future multiparticulate or alternate-delivery products.

Generic competition is fragmented. The relevant competitive advantages are manufacturing scale, FDA inspection history, product reliability, launch timing, contracting access and supply continuity.

A branded duloxetine product has limited ability to preserve price once several therapeutically equivalent generics are available. A differentiated formulation must offer a measurable advantage in administration, tolerability, adherence, supply reliability or payer economics.

What Paragraph IV challenges and litigation affect Irenka?

The major Paragraph IV risk period occurred during generic entry against the branded duloxetine reference product. The practical litigation issues included:

• Validity of delayed-release formulation patents.
• Infringement by generic pellet architectures.
• Use-code and method-of-use listings.
• At-risk launch exposure.
• Settlement timing.
• 180-day exclusivity for the first qualifying generic applicant.

Current Irenka-specific litigation risk should be assessed through active federal case records, FDA Orange Book patent listings and settlement disclosures. A historical Paragraph IV dispute does not establish a current barrier to entry.

For a new entrant, the principal litigation questions are:

1. Is any relevant patent still unexpired in the target market?
2. Does the proposed formulation practice a valid claim?
3. Can the product use a non-infringing enteric polymer system?
4. Can indication carve-outs avoid method-of-use claims?
5. Does the formulation create a new patentable product profile?

What generic launch scenarios exist for duloxetine?

Standard capsule launch

This is the lowest-risk regulatory strategy but the most price-sensitive. Success depends on manufacturing cost, supply reliability and contracting.

Differentiated enteric-coated capsule

A modified polymer or coating process can support a product-specific patent position, but FDA bioequivalence and dissolution requirements remain demanding.

Sprinkle capsule

This can support a targeted commercial proposition for patients with swallowing difficulty. The product requires administration and food-interaction validation.

Institutional multi-strength portfolio

A manufacturer with 20 mg, 30 mg, 40 mg and 60 mg strengths can improve tender competitiveness and reduce wholesaler substitution risk.

Regional manufacturing and licensing

A local manufacturer can use an established formulation platform to enter markets where import costs, procurement rules or supply shortages create an opening.

How does Irenka compare with Cymbalta and generic duloxetine?

Factor	Irenka	Cymbalta	Generic duloxetine
Active ingredient	Duloxetine hydrochloride	Duloxetine hydrochloride	Duloxetine hydrochloride
Release type	Delayed release	Delayed release	Delayed release
Brand premium	Limited or historical	Historically high	Low
Patent position	Dependent on formulation and jurisdiction	Core patents expired	Generally no core composition exclusivity
Main advantage	Product-specific positioning	Brand recognition and historical clinical familiarity	Price and supply competition
Excipient opportunity	Reformulation, coating and shell differentiation	Lifecycle management	Cost reduction and manufacturing efficiency
Main risk	Weak differentiation	Generic erosion	Margin compression

What revenue exposure does duloxetine create?

Duloxetine has broad chronic-use exposure across psychiatric, neuropathic-pain and musculoskeletal indications. That creates a large prescription base but also accelerates generic substitution.

Revenue exposure is highest for products that depend on:

• High-volume chronic indications.
• Retail pharmacy reimbursement.
• A small number of large customers.
• A narrow manufacturing network.
• A single enteric-polymer supplier.
• Limited inventory flexibility.

The most defensible value proposition is operational rather than brand-based: fewer batch failures, stable dissolution, lower coating cost, dependable supply and differentiated administration.

What geographic coverage matters for Irenka?

The United States is the most important market for Orange Book and Paragraph IV analysis. Europe, Canada, Japan, India and emerging markets require separate assessments because patent expiry, reference-product rules, data exclusivity, local manufacturing requirements and substitution practices differ.

A global excipient strategy should account for:

• FDA inactive-ingredient and quality expectations.
• European Pharmacopoeia and United States Pharmacopeia standards.
• Regional capsule-shell preferences.
• Local colorant restrictions.
• Supplier qualification requirements.
• Serialization and packaging rules.
• Country-specific patent term adjustments.

A polymer or capsule shell that is acceptable in the United States may require separate regulatory documentation in Europe or other markets.

Key Takeaways

• Irenka is a duloxetine hydrochloride delayed-release capsule whose commercial performance depends on enteric-release control, not active-ingredient exclusivity.
• The most important excipient systems are the enteric polymer, plasticizer, anti-tacking agent, pellet substrate and capsule shell.
• Conventional duloxetine composition protection is weak after patent expiry.
• Stronger commercial protection can come from sprinkle delivery, low-moisture formulations, novel pellet architecture and manufacturing-process know-how.
• Generic price competition limits the value of ordinary capsule reformulation.
• Excipient suppliers can capture value through coating efficiency, lower defect rates, validated global supply and stability improvement.
• Current Orange Book listings, active patents and litigation records must be reviewed by jurisdiction before licensing or launch decisions.
• The highest-probability opportunity is a cost-efficient, reliably manufactured delayed-release capsule supported by a differentiated administration or supply proposition.

FAQs

Can duloxetine delayed-release capsules use a different enteric polymer from Irenka?

Yes. A different enteric polymer may be used if the product meets FDA dissolution, stability, bioequivalence and quality requirements and does not infringe an unexpired patent.

Is a hypromellose capsule commercially better than a gelatin capsule for duloxetine?

It can support vegetarian positioning and may offer different moisture characteristics, but it does not create a commercial advantage without demonstrated stability, dissolution and market demand.

Can duloxetine pellets be converted into a liquid formulation?

A conventional aqueous liquid is technically challenging because duloxetine requires delayed release and gastric protection. Multiparticulate granules or a reconstituted system may be more feasible than a simple liquid.

Does an excipient change automatically create new patent protection?

No. A new excipient may support patentability only when the resulting composition, performance or clinical benefit is novel and non-obvious and the claims are properly drafted.

What is the main manufacturing bottleneck for duloxetine delayed-release capsules?

Fluid-bed drug layering and enteric coating are the main bottlenecks. Coating uniformity, pellet agglomeration, residual moisture, acid resistance and post-acid dissolution determine batch yield and product release.

References

1. U.S. Food and Drug Administration. (n.d.). Irenka duloxetine hydrochloride delayed-release capsules prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2018). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.

4. U.S. Food and Drug Administration. (2022). Inactive ingredient database. FDA.

5. Eli Lilly and Company. (n.d.). Cymbalta duloxetine delayed-release capsules prescribing information. U.S. Food and Drug Administration.

6. United States Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. USP.